media – Page 40 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Acquisition of Loss-Making Company to Consolidate Plasma Station Resources

Recently, TianTan Bio (600161.SH) announced that its controlling subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. (referred to as “Chengdu Rongsheng”) intends to acquire 100% of the shares of Wuhan Zhongyuan Ruide Biological Products Co., Ltd. (referred to as “Zhongyuan Ruide”), a wholly-owned subsidiary of CSL Behring Asia Pacific Limited (“CSL Asia Pacific”), for a total amount of $185 million (approximately 1.317 billion yuan). After the completion of this transaction, Zhongyuan Ruide will become a controlled subsidiary of TianTan Bio, and its financial statements will be consolidated. TianTan Bio indicated that it will add a new blood product production enterprise and five operational blood plasma collection stations. According to reporters from China Business Journal, Zhongyuan Ruide was acquired by CSL Asia Pacific between 2017 and 2018 through its subsidiary CSL Behring. However, after seven years, CSL Asia Pacific has chosen to sell at a discounted price. Additionally, the company is currently in ...
- Source: drugdu
- 102
- September 14, 2024
Increasing Investment in R&D Innovation to Deepen Product Competitive Moats

CSPC Pharmaceutical Group has achieved significant milestones in research and development, securing conditional approval for its self-developed Class 1 new drug, Enlansub, and for the injectable version of Rayzoprazole. The company has also received approval for clinical trials in the U.S. for its antibody-drug conjugate, clinical trial approval for its mRNA vaccine against respiratory syncytial virus, and clinical trial approval for the first CAR-T cell injection based on mRNA-LNP technology. As an innovation-driven enterprise and a key player in the national industrial chain, CSPC continues to enhance its R&D investments, elevate its international influence, and fortify its product competitive edge. This year, various in-development drugs have reached key progress points, with some approved for market launch or clinical trials both domestically and internationally. Currently, CSPC is conducting over 130 innovative drug projects, with more than 50 new drugs expected to be launched in the next five years. Comprehensive Market Coverage ...
- Source: drugdu
- 72
- September 14, 2024
Another new COPD drug is coming

On September 6, GlaxoSmithKline (GSK) announced that its Phase 3 MATINEE study of its IL-5 antibody Nucala (mepolizumab) in the treatment of COPD achieved positive results. Compared with the placebo group, the Nucala treatment group achieved a statistically significant reduction in the annualized rate of moderate to severe exacerbations, but specific data have not yet been released. Two months ago, two COPD drugs with new mechanisms: ensifentrine and dupilumab were approved for marketing in the United States and Europe, refreshing the treatment model of this severe respiratory disease. Mepolizumab is expected to join this new round of competition. COPD: The third leading cause of death in humans Chronic obstructive pulmonary disease (COPD), referred to as COPD, is a common, preventable and treatable heterogeneous disease. According to statistics from the World Health Organization, COPD has become the third leading cause of death in humans, with about 11% of people dying from ...
- Source: drugdu
- 63
- September 14, 2024
Ascentage Pharma’s “Nerlik®” received an oral presentation

Ascentage Pharma (6855.HK) announced today that the company has published the clinical research results of the company’s original Class 1 new drug Olebatinib (trade name: Nerlik®; research and development code: HQP1351) for the treatment of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) in the form of a mini oral presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. The clinical data of this oral presentation showed that Olebatinib has sustained clinical efficacy in the treatment of SDH-deficient GIST. As of March 12, 2024, 6 of the 26 patients with SDH-deficient GIST enrolled achieved partial remission (PR), the objective response rate (ORR) was 23.1%, and the median progression-free survival (PFS) was 22 months. In addition, potential mechanism of action (MOA) studies have shown that orebactinib exerts anti-tumor activity by regulating multiple signaling pathways involved in angiogenesis, apoptosis, proliferation and survival. Orebactinib is an original Class 1 new drug ...
- Source: drugdu
- 64
- September 14, 2024
Traditional Chinese Medicine Brands Accelerate Penetration into Young Consumer Groups

In recent years, health-oriented and personalized dietary trends, exemplified by new-style tea beverages, have rapidly gained popularity among young consumers. Building on this foundation, with an increasing awareness of health and wellness, traditional Chinese medicine (TCM) health drinks, with their unique health philosophies and rich cultural backgrounds, have gradually won recognition among younger demographics. Reports from the China Securities Journal indicate that it’s not just beverage products; under consumer demand, renowned TCM brands such as Tong Han Chun Tang, Tong Ren Tang, Lei Yun Shang, and Hu Qing Yu Tang are actively launching new products featuring TCM ingredients, including medicinal dishes, herbal scents, and skincare items, tailored to meet the genuine needs of younger consumers. Experts believe that as these brands expand their product lines and target consumption scenarios, it will help rejuvenate the long-standing TCM brands. Targeting Youth to Enhance Product Offerings Historically, traditional TCM shops have not been ...
- Source: drugdu
- 94
- September 13, 2024
Focusing on the Frontiers of Biomedicine and Creating an Open Source Innovation Ecosystem.

Recently, a reporter from China Securities Journal visited the Shanghai Frontier Biomedical Innovation Center. Driving into the core area of the Zhangjiang Science City, a national-level biomedical base, one can see a modern, curved building from afar. Approaching closer, the open interior, visible through the yellow and white glass, creates a sense of freedom and positivity. “Currently, 10 resident companies and 11 ecological partners have signed cooperation agreements with Shanghai Frontier,” a representative from Shanghai Frontier stated. The center aims to create a “wall-less R&D center,” breaking down traditional barriers and promoting interaction and collaboration among experts, scholars, businesses, and investors from various fields and backgrounds, including industry, education, research, healthcare, and finance. Looking ahead, Shanghai Frontier will focus on cutting-edge biotechnologies such as gene and cell therapy, nucleic acid drugs, and conjugated drugs, hoping to discover and nurture highly innovative and competitive companies and projects while encouraging high-potential innovations ...
- Source: drugdu
- 110
- September 13, 2024
A domestic giant in imaging equipment

Imaging equipment is an indispensable medical product for building a clinical diagnosis and treatment system. Medical imaging equipment interacts with the human body through a certain medium (such as X-rays, electromagnetic fields, ultrasound, etc.), and presents the structure and density of internal tissues and organs of the human body in the form of images for diagnostic physicians to judge and evaluate the health status of the human body. Commonly used medical imaging equipment in clinical practice includes computed tomography (CT), magnetic resonance imaging (MR), X-ray imaging equipment, nuclear medicine diagnostic equipment, and ultrasound equipment (US). Medical imaging of different modalities has different working principles, imaging characteristics, application scenarios, and advantages and disadvantages, but the functions are relatively consistent: Medical imaging equipment is one of the basic diagnostic options before most diseases are currently intervened, especially in the context of aging in China. Most aging-related diseases such as cardiovascular and cerebrovascular ...
- Source: drugdu
- 83
- September 13, 2024
A Chinese innovative pharmaceutical company “died”

On September 5, Connect (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company headquartered in the United States, announced its financial results for the six months ended June 30, 2024 and announced plans to large-scale attrition. In addition, as part of Connect’s transformation into a U.S.-focused company, the company plans to significantly reduce the scale of its operations in China. Just a few months ago, Connect was an innovative pharmaceutical company in China. All these changes are rooted in the clinical setbacks of Connect’s core pipeline product, Rademikibart (CBP-201). This is a fully human monoclonal antibody targeting IL-4Rα, which is a common subunit of IL-4Rα and IL-13 receptors. It directly targets Sanofi’s new autoimmune drug Duprilumab. anti. In the CBP-201 clinical data previously announced by Connect, although some connotations of long-term efficacy data were seen, the improvement in the 16-week data was weaker than that of dupilumab; in addition, because it was ...
- Source: drugdu
- 54
- September 13, 2024
Ultrasonic Knife Alliance’s centralized procurement is imminent, how can China’s brands “overtake on the bend”

On September 3, 2024, the Shenzhen Public Resource Trading Center once again publicly solicited opinions on the “Continuation of Procurement Documents for Centralized Volume Purchase Agreement of Ultrasonic Knife Heads and Pre filled Catheter Flushers (Draft for Comments)”. Enterprises can provide feedback before 17:00 on September 10. The variety of this procurement is ultrasonic blade head (disposable/reusable/integrated handle ultrasonic blade head). After two years, this market is once again experiencing a tense moment. The Guangdong Alliance’s centralized procurement of ultrasonic knives will be launched, and market competition has entered a white hot stage Since the first centralized procurement of ultrasonic cutting heads in Fujian Province in 2020, as of 2024, the centralized procurement areas for ultrasonic cutting heads have spread throughout the country. After this launch, the Guangdong Alliance will become the largest alliance for centralized procurement of ultrasonic knives. At the end of 2021, Guangdong led a 16 province ...
- Source: drugdu
- 80
- September 13, 2024
Two innovative medical devices from Medtronic have been approved for market in China

Recently, the National Medical Products Administration announced the approval of Medtronic’s registration applications for two innovative products, the “Heart Pulse Electric Field Ablation Generator” and the “Disposable Heart Pulse Electric Field Ablation Catheter”. Unique advantages, suitable for two indications It is reported that the two innovative products approved this time are Medtronic’s PFA product – PulseSelect, which is the first PFA product approved by NMPA that can be used for both paroxysmal and persistent atrial fibrillation. PulseSelect is a new technique for treating atrial fibrillation (AF) using pulsed electric fields, which can provide bipolar and biphasic pulsed electric fields through a circular multi electrode array catheter. This technology consists of five parts: a controllable multi electrode annular ablation catheter, a PFA host ECG-Gated、 Tableside control、10Fr bidirectional sheath. It is worth mentioning that PulseSelect’s controllable multi electrode annular ablation catheter features a proprietary biphasic waveform, unique built-in guide wire, and a ...
- Source: drugdu
- 98
- September 13, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.